All In Biotech

Drug Trial Radar · NCT07680764

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Sep 15, 2028

Study completion Sep 15, 2030

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Conditions

  • Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • PumitamigDrug

    Specified dose on specified days

  • ImzokitugDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • PaclitaxelDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) by investigator (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)Time frame: Up to approximately 4 years

Locations

74 sites in 12 countries. Site status is shown where the registry gives one.

  • Local Institution - 0183

    Washington D.C., District of Columbia · Not yet recruiting

  • University Cancer & Blood Center, LLC

    Athens, Georgia · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • Baptist Health Hamburg

    Lexington, Kentucky · Recruiting

  • Local Institution - 0123

    Baltimore, Maryland · Not yet recruiting

  • Hattiesburg Clinic

    Hattiesburg, Mississippi · Recruiting

  • Nebraska Cancer Specialists

    Grand Island, Nebraska · Recruiting

  • Oncology Hematology West PC

    Omaha, Nebraska · Recruiting

  • Local Institution - 0080

    New York, New York · Not yet recruiting

  • Local Institution - 0176

    Columbus, Ohio · Not yet recruiting

  • Local Institution - 0095

    Houston, Texas · Not yet recruiting

  • Local Institution - 0135

    Madison, Wisconsin · Not yet recruiting

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Argentina · Recruiting

  • Clinica Viedma S.A.

    Viedma, Argentina · Recruiting

  • Sanatorio Parque Rosario

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Gosford Hospital

    Gosford, New South Wales, Australia · Recruiting

  • Local Institution - 0134

    Westmead, New South Wales, Australia · Not yet recruiting

  • Local Institution - 0167

    Greenslopes, Queensland, Australia · Not yet recruiting

  • Local Institution - 0100

    Heidelberg, Victoria, Australia · Not yet recruiting

  • St. John of God Murdoch Hospital

    Perth, Western Australia, Australia · Recruiting

  • Local Institution - 0001

    São Paulo, Brazil · Not yet recruiting

  • Local Institution - 0003

    Natal/RN, Rio Grande do Norte, Brazil · Not yet recruiting

  • Local Institution - 0006

    Porto Alegre, Rio Grande do Sul, Brazil · Not yet recruiting

  • Local Institution - 0005

    Barretos, São Paulo, Brazil · Not yet recruiting

  • Orlandi Oncologia

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • Bradfordhill

    Santiago, Santiago Metropolitan, Chile · Recruiting

  • Oncocentro Apys

    Viña del Mar, Valparaiso, Chile · Recruiting

  • Local Institution - 0038

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Local Institution - 0138

    Fuzhou, Fujian, China · Not yet recruiting

  • Local Institution - 0050

    Wuhan, Hubei, China · Not yet recruiting

  • Local Institution - 0147

    Nanjing, Jiangsu, China · Not yet recruiting

  • Local Institution - 0140

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Local Institution - 0169

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Local Institution - 0144

    Chengdu, Sichuan, China · Not yet recruiting

  • Local Institution - 0137

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Local Institution - 0047

    Grenoble, France · Not yet recruiting

  • Assistance Publique Hôpitaux de Marseille - Hôpital Nord

    Marseille, France · Recruiting

  • Hopitaux Universitaires Paris Centre-Hopital Cochin

    Paris, France · Recruiting

  • Local Institution - 0085

    Saint-Herblain, France · Not yet recruiting

  • Local Institution - 0131

    Nice, Alpes-Maritimes, France · Not yet recruiting

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.